Progress and Controversies in Gynecologic Oncology Conference

Transcription

1 2016 Progress and Controversies in Gynecologic Oncology Conference January 2016 Crowne Plaza Barcelona - Fira Center Barcelona, Spain

2 Welcome On behalf of the co-chairs and Scientific Committee, we are pleased to invite you to the 2016 Progress and Controversies in Gynecologic Oncology Conference, to be held in Barcelona, Spain, on January This meeting will serve as a valuable forum for the presentation and discussion of newly available data across various gynecologic malignancies, including ovarian, cervical, and endometrial cancers. Participants will be provided with updates on practice-changing data in a practical and interactive format, fostering discussion, and impacting clinical outcomes for patients. Who Should Attend The 2016 Progress and Controversies in Gynecology Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals involved in the management of gynecologic malignancies. Learning Objectives After successful completion of this educational activity, participants should be able to: * Develop a practical approach to cervical cancer and vulvar cancer disease management * Describe the role of various therapeutic modalities in the management of endometrial cancer * Derive the optimal management of ovarian cancer based on disease stage and clinical presentation * Assess standard and emerging therapeutic options for recurrent ovarian cancer and discuss their impact on patient outcomes * Discuss contemporary strategies for the management of various rare gynecologic malignancies Continuing Education An application has been made to the EACCME for CME Accreditation of this event. Venue Crowne Plaza Barcelona - Fira Center Avda Rius I Taulet, 1-3 Barcelona, Spain Co-Chairs Andreas du Bois, MD, PhD Kliniken Essen-Mitte Essen, Germany Stanley B. Kaye, MD The Royal Marsden Hospital Sutton, United Kingdom Ignace Vergote, MD, PhD University Hospital Gasthuisberg Leuven, European Union Scientific Committee Nicoletta Colombo, MD University of Milan-Bicocca Milan, Italy Bradley J. Monk, MD, FACS, FACOG Creighton University School of Medicine at St Joseph s Hospital and Medical Center Phoenix, Arizona, United States Andrés Poveda, MD Fundación Instituto Valenciano de Oncología Valencia, Spain Eric Pujade-Lauraine, MD, PhD Centre Hospitalier Universitaire Hôtel-Dieu Paris, France CPD approval has been sought from the Federation of the Royal Colleges of Physicians. Provider This educational activity is provided by prime Oncology. All inquiries related to the 2016 Progress and Controversies in Gynecologic Oncology Conference may be addressed to: gyncongress2016@primeoncology.org

3 Registration Registration Fees Early Regular Late/Onsite Physician 375,- 475,- 575,- Nurse 225,- 300,- 350,- Fellow/Resident/Student* 225,- 300,- 350,- Industry 425,- 525,- 625,- Registration fees include VAT. *Supporting documentation of eligibility may be required. Your registration fee will include: * Access to all sessions and exhibition * Lunch and coffee breaks * Congress documentation Registration Deadlines Early registration rate: 1 November 2015 (23.59 CET) Regular registration rate: 29 November 2015 (23.59 CET) To Register You may register online through 20 January 2016 at Registration confirmations will be issued upon successful completion of registration and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than 1 November 2015 (early registration rate) or 30 November 2015 (regular registration rate). Please register onsite after 20 January Accommodation A limited number of rooms are available at the Crowne Plaza Barcelona - Fira Center (meeting venue). Delegates are recommended to make their hotel reservation as early as possible. You can book your hotel room with the online registration form at the registration tab at or send an to registrations.gyn@primeoncology.org. Complete congress information and registration available at: Group Registrations Group registration will be accepted. For more information, please contact: registrations.gyn2016@primeoncology.org. Terms of Payment All payments must be made in Euros. Payments can be made by credit card. Registration will only be valid upon receipt of full payment by prime Oncology. Outstanding payment must be settled onsite by credit card. Cancellation To receive a refund of registration fees, written notice of cancellation must be received at registrations.gyn2015@primeoncology.org. The following deadlines and cancellation fee schedule will apply: * Before 1 November 2015: 50,- administrative charge * From 1 November 2015: 60% cancellation fee applies on registration fee(s) * From 30 November 2015: 100% cancellation fee applies on registration fee(s) * Name changes from 30 November 2015: 15,- fee is charged per change Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 29 November prime Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

4 Agenda Friday, 22 January Welcome and introduction Keynote lecture Immunotherapy in gynecologic malignancies Session I Cervical Cancer and Vulvar Cancer Reconstructive surgery for vulvar cancer Debate Neoadjuvant chemotherapy versus primary radiochemotherapy in FIGO IB2 cervical cancer Neoadjuvant chemotherapy Primary radiochemotherapy Targeted therapy and immunotherapy for cervical cancer Break Session II Endometrial Cancer Sentinel node biopsy in endometrial cancer: Ready for prime time? Systemic treatment of endometrial cancer: Are there any new agents in sight? How to incorporate clinical trials into routine daily clinical practice Day 1 concluding remarks and adjourn Agenda Saturday, 23 January Welcome and introduction Session III Ovarian Neoplasm I: Recurrence State of the art: Platinum-resistant disease State of the art: Platinum-sensitive disease Strategies for ovarian cancer patients who have received multiple prior therapies Break Session IV Ovarian Neoplasm II: Emerging Concepts News from the 5th Ovarian Cancer Consensus Conference: Consequences for clinical practice? Genetic testing for ovarian cancer: When, how, and who? DNA repair inhibitors as targeted agents: Current status and future strategies Break Industry-supported satellite symposium Break Session V Ovarian Neoplasm III: Practical Issues Residual tumor following surgery: The strongest prognostic factor or a myth? Thoracic surgery in ovarian cancer: Why, when, and how? Session VI Rare Tumors: State of the Art Sex cord tumors Gestational trophoblastic neoplasia Uterine sarcoma Day 2 concluding remarks Adjourn

5 Support This educational event is industry-supported. * Saturday s satellite symposium is supported by F. Hoffmann-La Roche Ltd EU Office prime Oncology Schenkkade 50, Suite AR The Hague the Netherlands Additional information and registration available at: 2016 prime Oncology